Senti Biosciences reported financial results for Q2 2025, achieving RP2D for SENTI-202 in Phase 1 study for AML. Orphan Drug Designation granted for AML treatment, $1.0M from CIRM grant received, and leadership team strengthened with new appointments. Expect additional data from Phase 1 study by year-end.

Senti Bio participated in Nasdaq’s Amplify Spotlight Series and presented at scientific conferences. Engaged in virtual events to increase market visibility. Financially, Senti Bio had $21.6M in cash as of June 30, 2025, with R&D expenses at $10.0M and G&A expenses at $6.8M for Q2 2025, resulting in a net loss of $14.7M.

Senti Bio is a biotech company developing cell and gene therapies for incurable diseases using Gene Circuits. Their pipeline targets liquid and solid tumors, with promising preclinical results in NK and T cells. Forward-looking statements highlight growth, clinical trial progress, and potential risks affecting future outcomes.

Financial data for Senti Biosciences shows cash holdings of $21.6M as of June 30, 2025, with total assets at $68.5M and liabilities at $43.9M. Operating expenses for Q2 2025 included R&D expenses of $10.0M and G&A expenses of $6.8M, resulting in a net loss of $14.7M. Basic and diluted net loss per share was $0.56.

Read more at GlobeNewswire: Senti Bio Reports Second Quarter 2025 Financial Results and